{"id":5512,"date":"2026-01-31T12:29:03","date_gmt":"2026-01-31T09:29:03","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5512"},"modified":"2026-01-31T13:15:17","modified_gmt":"2026-01-31T10:15:17","slug":"sonothera-ripple-ultrasound-mediated-delivery-full-length-human-dystrophin","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/sonothera-ripple-ultrasound-mediated-delivery-full-length-human-dystrophin\/","title":{"rendered":"SonoThera'n\u0131n RIPPLE Teknolojisi, Tam Uzunlukta \u0130nsan Distrofini \u0130\u00e7in Umut Vadediyor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Genetik ila\u00e7lar\u0131n yeni neslini geli\u015ftirerek insan hastal\u0131klar\u0131n\u0131n temel nedenlerini tedavi etmeyi ama\u00e7layan bir biyoteknoloji \u015firketi olan SonoThera, 8 Ocak 2026&#039;da, tescilli RIPPLE\u2122 teknolojisinin, insan d\u0131\u015f\u0131 primatlar\u0131n iskelet kaslar\u0131nda g\u00fc\u00e7l\u00fc ve kal\u0131c\u0131 tam uzunlukta insan distrofin protein ekspresyonunu tespit etti\u011fini ve bunun normal seviyelerin 290%&#039;sine kadar ula\u015ft\u0131\u011f\u0131n\u0131 duyurdu.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#sono-theras-nonviral-platform-ripple\">SonoThera'n\u0131n vir\u00fcs i\u00e7ermeyen platformu: RIPPLE<\/a><\/li><li><a href=\"#datas-of-full-length-human-dystrophin-raises-expectations\">Tam uzunlukta insan distrofini beklentileri art\u0131r\u0131yor<\/a><\/li><li><a href=\"#questions-we-asked-sono-thera-and-their-answers\">SonoThera'ya Sordu\u011fumuz Sorular ve Ald\u0131\u011f\u0131m\u0131z Cevaplar<\/a><ul><li><a href=\"#in-your-press-release-you-mentioned-conducting-a-study-on-non-human-primates-in-this-study-which-genetic-medicine-did-you-use-to-deliver-to-organs-using-umd-technology\">SonoThera'n\u0131n bas\u0131n b\u00fclteninde \u015firket, insan d\u0131\u015f\u0131 primatlar \u00fczerinde bir \u00e7al\u0131\u015fma y\u00fcr\u00fctt\u00fc\u011f\u00fcnden bahsetti. Bu \u00e7al\u0131\u015fmada \u015firket, UMD teknolojisini kullanarak organlara hangi genetik ilac\u0131 iletti?<\/a><\/li><li><a href=\"#to-confirm-we-ask-are-you-using-a-genetic-medicine-developed-in-house-by-sono-thera-using-umd-that-is-not-a-gene-therapy-that-is-already-on-the-market-or-undergoing-clinical-trials-are-you-using-a-gene-medicine-that-is-entirely-owned-by-sono-thera\">Bunu do\u011frulamak i\u00e7in \u015funu soruyoruz: SonoThera, kurum i\u00e7inde geli\u015ftirilmi\u015f bir genetik ila\u00e7 m\u0131 kullan\u0131yor? Yani, halihaz\u0131rda piyasada olan veya klinik denemelerden ge\u00e7en bir gen terapisi de\u011fil!<\/a><\/li><li><a href=\"#which-tests-were-used-to-determine-if-full-length-dystrophin-production-was-achieved-did-you-measure-it-via-muscle-biopsy\">Tam uzunlukta distrofin \u00fcretiminin sa\u011flan\u0131p sa\u011flanmad\u0131\u011f\u0131n\u0131 belirlemek i\u00e7in hangi testler kullan\u0131ld\u0131? SonoThera bunu kas biyopsisi yoluyla m\u0131 \u00f6l\u00e7t\u00fc?<\/a><\/li><li><a href=\"#did-you-have-the-opportunity-to-see-the-creatine-kinase-ast-and-alt-results-how-much-did-these-values-decrease\">SonoThera'n\u0131n Kreatin Kinaz, AST ve ALT sonu\u00e7lar\u0131n\u0131 g\u00f6rme f\u0131rsat\u0131 oldu mu? Bu de\u011ferler ne kadar azald\u0131?<\/a><\/li><li><a href=\"#when-do-you-plan-to-begin-studies-on-humans\">SonoThera insan \u00fczerinde yap\u0131lacak \u00e7al\u0131\u015fmalara ne zaman ba\u015flamay\u0131 planl\u0131yor?<\/a><\/li><\/ul><\/li><li><a href=\"#the-road-to-clinic-trials\">Klinik ara\u015ft\u0131rmalara giden yol<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>SonoThera'n\u0131n RIPPLE teknolojisi hakk\u0131nda daha fazla bilgi edinmek i\u00e7in Kurumsal \u0130leti\u015fim departman\u0131ndan Elizabeth Harness ile ileti\u015fime ge\u00e7tik ve takip\u00e7ilerimiz ad\u0131na sorular\u0131m\u0131z\u0131 ilettik.<\/strong> Elizabeth, Duchenne kas distrofisinde de kullan\u0131lmas\u0131 planlanan Ultrason Destekli \u0130la\u00e7 Uygulamas\u0131 (UMD) teknolojisi hakk\u0131nda ayr\u0131nt\u0131l\u0131 ve \u00f6zenli bir \u015fekilde bilgi verdi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">G\u00fcney San Francisco merkezli genetik t\u0131p \u015firketi SonoThera, 44. JP Morgan Sa\u011fl\u0131k Konferans\u0131&#039;nda 125 milyon dolarl\u0131k B Serisi finansman turunun ba\u015flat\u0131ld\u0131\u011f\u0131n\u0131 duyurdu. Elde edilen sermaye, Duchenne kas distrofisi (DMD), otozomal dominant polikistik b\u00f6brek hastal\u0131\u011f\u0131 (ADPKD) ve X&#039;e ba\u011fl\u0131 Alport sendromu (XLAS) hedefleyen \u00fc\u00e7 \u00f6nc\u00fc program i\u00e7in insanlarda ilk klinik \u00e7al\u0131\u015fmalar\u0131 ilerletmek i\u00e7in kullan\u0131lacak. <strong>Bu programlar, SonoThera'n\u0131n tescilli RIPPLE platformundan yararlanacak. Bu platform, viral vekt\u00f6rlerin s\u0131n\u0131rlamalar\u0131n\u0131n \u00fcstesinden gelmek i\u00e7in tasarlanm\u0131\u015f, vir\u00fcs i\u00e7ermeyen, ultrason arac\u0131l\u0131 bir da\u011f\u0131t\u0131m teknolojisidir ve hedeflenmi\u015f, boyuttan ba\u011f\u0131ms\u0131z y\u00fck da\u011f\u0131t\u0131m\u0131n\u0131 m\u00fcmk\u00fcn k\u0131larak \u00f6l\u00e7eklenebilir ve tekrarlanabilir gen terapisi geli\u015fimini destekler.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sono-theras-nonviral-platform-ripple\">SonoThera'n\u0131n vir\u00fcs i\u00e7ermeyen platformu: RIPPLE<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SonoThera'n\u0131n genetik iletim yakla\u015f\u0131m\u0131, gen terapisindeki en kal\u0131c\u0131 zorluklardan birine, yani viral vekt\u00f6rlerin do\u011fas\u0131nda var olan s\u0131n\u0131rlamalara do\u011frudan \u00e7\u00f6z\u00fcm getiriyor. Adeno-ili\u015fkili vir\u00fcs (AAV) yayg\u0131n iletim y\u00f6ntemi olmaya devam etse de, yakla\u015f\u0131k 4,7 kb'l\u0131k nispeten k\u00fc\u00e7\u00fck bir y\u00fck kapasitesi, potansiyel imm\u00fcnojenik yan\u0131tlar ve n\u00f6tralize edici antikorlar\u0131n geli\u015fmesi nedeniyle tekrarlanan dozlamayla ilgili zorluklarla s\u0131n\u0131rl\u0131d\u0131r. Bu dezavantajlar, \u00f6zellikle b\u00fcy\u00fck genetik dizilerin iletimini gerektiren durumlar i\u00e7in sorun te\u015fkil etmektedir; Duchenne kas distrofisi bunun a\u00e7\u0131k bir \u00f6rne\u011fidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u015eirketin ultrason destekli ila\u00e7 iletimini (UMD) kullanan RIPPLE platformu, bu engelleri a\u015fmak i\u00e7in tasarlanm\u0131\u015ft\u0131r.<\/strong> Odaklanm\u0131\u015f ultrasonu mikrobaloncuk aktivasyonuyla birle\u015ftirerek, bu teknoloji h\u00fccre zar\u0131 ge\u00e7irgenli\u011fini ge\u00e7ici olarak art\u0131r\u0131r ve b\u00f6ylece y\u00fck boyutundan ba\u011f\u0131ms\u0131z olarak genetik materyalin hedeflenmi\u015f al\u0131m\u0131n\u0131 m\u00fcmk\u00fcn k\u0131lar. Daha da \u00f6nemlisi, platform tekrarlanabilir, uzun \u00f6m\u00fcrl\u00fc ve tam uzunlukta gen iletimine uygun olarak konumland\u0131r\u0131lm\u0131\u015ft\u0131r; bu da geleneksel vekt\u00f6r tabanl\u0131 sistemler kullan\u0131larak ele al\u0131nmas\u0131 zor olan hastal\u0131klar i\u00e7in tedavi olanaklar\u0131 a\u00e7maktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha geni\u015f bir platform a\u00e7\u0131s\u0131ndan bak\u0131ld\u0131\u011f\u0131nda, RIPPLE, da\u011f\u0131t\u0131m teknolojisinde kademeli bir ilerlemeden daha fazlas\u0131n\u0131 temsil ediyor. Sekt\u00f6r g\u00f6zlemcileri, \u00f6zellikle devam eden \u00fcretim ve g\u00fcvenlik zorluklar\u0131na yan\u0131t olarak viral vekt\u00f6rlere y\u00f6nelik d\u00fczenleyici incelemelerin yo\u011funla\u015fmas\u0131yla birlikte, bunun yeni bir viral olmayan, cihaz destekli gen terapisi s\u0131n\u0131f\u0131n\u0131n tan\u0131mlanmas\u0131na yard\u0131mc\u0131 olabilece\u011fini \u00f6ne s\u00fcr\u00fcyor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"datas-of-full-length-human-dystrophin-raises-expectations\">Tam uzunlukta insan distrofini beklentileri art\u0131r\u0131yor<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>DMD'nin \u00f6ncelikli endikasyon olarak se\u00e7ilmesi, SonoThera'n\u0131n mevcut tedavi paradigmalar\u0131n\u0131n s\u0131n\u0131rlamalar\u0131n\u0131n \u00f6tesine ge\u00e7meyi hedefledi\u011fini g\u00f6stermektedir.<\/strong> \u015eu anda onaylanm\u0131\u015f olan DMD i\u00e7in AAV tabanl\u0131 tedaviler, Sarepta Therapeutics&#039; ve Elevidys dahil olmak \u00fczere, AAV vekt\u00f6rlerinin getirdi\u011fi kat\u0131 y\u00fck k\u0131s\u0131tlamalar\u0131 nedeniyle mikro-distrofin yap\u0131lar\u0131na ba\u011fl\u0131d\u0131r. Bu k\u0131salt\u0131lm\u0131\u015f genler hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatabilse de, iyile\u015ftirici de\u011fildir ve kas fonksiyonunu tamamen geri kazand\u0131rmaz.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Buna kar\u015f\u0131l\u0131k, SonoThera, insan d\u0131\u015f\u0131 primatlar\u0131n iskelet kaslar\u0131nda tam uzunlukta insan distrofininin normal seviyelere (290%) kadar ula\u015fan d\u00fczeylerde ekspresyonunu rapor etmi\u015f ve kemirgen modellerinde kas g\u00fcc\u00fcnde iyile\u015fme g\u00f6stermi\u015ftir.<\/strong>. Bu sonu\u00e7lar klinik ortamlara k\u0131smen bile olsa yans\u0131rsa, DMD tedavisinde d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc bir ilerlemeyi temsil edebilir ve potansiyel olarak Becker kas distrofisinde veya asemptomatik distrofin mutasyonu ta\u015f\u0131y\u0131c\u0131lar\u0131nda g\u00f6zlemlenenlere yakla\u015fan tedavi edici fayda d\u00fczeylerine ula\u015fabilir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"questions-we-asked-sono-thera-and-their-answers\">SonoThera'ya Sordu\u011fumuz Sorular ve Ald\u0131\u011f\u0131m\u0131z Cevaplar<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"in-your-press-release-you-mentioned-conducting-a-study-on-non-human-primates-in-this-study-which-genetic-medicine-did-you-use-to-deliver-to-organs-using-umd-technology\"><strong>SonoThera'n\u0131n bas\u0131n b\u00fclteninde \u015firket, insan d\u0131\u015f\u0131 primatlar \u00fczerinde bir \u00e7al\u0131\u015fma y\u00fcr\u00fctt\u00fc\u011f\u00fcnden bahsetti. Bu \u00e7al\u0131\u015fmada \u015firket, UMD teknolojisini kullanarak organlara hangi genetik ilac\u0131 iletti?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Genetik t\u0131p, bir\u00e7ok gen terapisi t\u00fcr\u00fcn\u00fc i\u00e7eren geni\u015f bir kategoridir. <strong>SonoThera bir gen terapisi \u015firketidir; ancak, halihaz\u0131rda onaylanm\u0131\u015f DMD gen terapilerinin aksine, AAV gibi viral ta\u015f\u0131y\u0131c\u0131 ara\u00e7lar kullanm\u0131yoruz.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bunun yerine, SonoThera, RIPPLE\u2122 ad\u0131 verilen yeni, vir\u00fcs i\u00e7ermeyen bir gen iletim platformu geli\u015ftirdi. RIPPLE\u2122, mevcut gen iletim yakla\u015f\u0131mlar\u0131n\u0131n g\u00fcvenlik, etkinlik ve maliyet\/\u00fcretim s\u0131n\u0131rlamalar\u0131n\u0131n \u00fcstesinden gelmek i\u00e7in \u00f6zel olarak tasarland\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Geli\u015ftirdi\u011fimiz \u00f6zel y\u00f6ntem, genetik y\u00fcklerin hedef organda g\u00fcvenli, verimli ve homojen bir \u015fekilde biyolojik da\u011f\u0131l\u0131m\u0131n\u0131 sa\u011flar. <strong>Duchenne kas distrofisinde, hedef d\u0131\u015f\u0131 iletim riskini en aza indirirken, tam uzunlukta distrofin kodlayan bir DNA molek\u00fcl\u00fcn\u00fcn iskelet kas\u0131na, kalbe ve diyaframa iletilmesine odaklan\u0131yoruz.<\/strong> RIPPLE\u2122 vir\u00fcs i\u00e7ermedi\u011fi i\u00e7in ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden gizlenir ve onaylanm\u0131\u015f DMD tedavilerinde kullan\u0131lan gen aktar\u0131m platformlar\u0131ndan temel olarak farkl\u0131d\u0131r. Teknoloji ayr\u0131ca dayan\u0131kl\u0131 ve tekrarlanabilir olacak \u015fekilde tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>RIPPLE\u2122, genetik y\u00fckleri invaziv olmayan bir \u015fekilde iletmek i\u00e7in piyasada bulunan ultrason sistemlerini, problar\u0131 ve mikrobaloncuklar\u0131 kullan\u0131r.<\/strong> Mikrobaloncuklar ve genetik y\u00fck birlikte intraven\u00f6z olarak verilir ve v\u00fccutta dola\u015f\u0131r. Daha sonra ultrason enerjisi \u00f6zellikle hedef dokuya uygulan\u0131r, bu da mikrobaloncuklar\u0131n \u00e7\u00f6kmesine ve ge\u00e7ici g\u00f6zenekler olu\u015fturmas\u0131na neden olur. <strong>Bu sayede genetik y\u00fck kan damarlar\u0131ndan \u00e7\u0131karak kas h\u00fccrelerine girer ve daha sonra gen ifadesinin ger\u00e7ekle\u015febilece\u011fi \u00e7ekirde\u011fe ula\u015f\u0131r.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"to-confirm-we-ask-are-you-using-a-genetic-medicine-developed-in-house-by-sono-thera-using-umd-that-is-not-a-gene-therapy-that-is-already-on-the-market-or-undergoing-clinical-trials-are-you-using-a-gene-medicine-that-is-entirely-owned-by-sono-thera\"><strong>Bunu do\u011frulamak i\u00e7in \u015funu soruyoruz: SonoThera, kurum i\u00e7inde geli\u015ftirilmi\u015f bir genetik ila\u00e7 m\u0131 kullan\u0131yor? Yani, halihaz\u0131rda piyasada olan veya klinik denemelerden ge\u00e7en bir gen terapisi de\u011fil!<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">SonoThera, genetik y\u00fckleri invaziv olmayan bir \u015fekilde iletmek i\u00e7in ticari olarak temin edilebilen ultrason sistemleri, problar ve mikrobaloncuklar kullanan RIPPLE\u2122 adl\u0131 yeni, vir\u00fcs i\u00e7ermeyen bir da\u011f\u0131t\u0131m platformu geli\u015ftirmi\u015ftir. Genetik y\u00fckler veya &quot;ila\u00e7lar&quot; a\u00e7\u0131s\u0131ndan yakla\u015f\u0131m\u0131m\u0131z, boyut s\u0131n\u0131rlamas\u0131 olmaks\u0131z\u0131n \u00e7e\u015fitli farkl\u0131 genetik y\u00fck t\u00fcrlerini kullanmam\u0131za olanak tan\u0131r. <strong>En \u00f6nemlisi, AAV gibi viral ta\u015f\u0131y\u0131c\u0131 ara\u00e7lar kullanm\u0131yoruz, bu nedenle yakla\u015f\u0131m\u0131m\u0131z viral olmayan bir yakla\u015f\u0131md\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD \u00e7al\u0131\u015fmas\u0131 i\u00e7in kulland\u0131\u011f\u0131m\u0131z y\u00fck a\u00e7\u0131s\u0131ndan, h\u00fccre replasman\u0131 i\u00e7in DNA kullan\u0131yoruz. <strong>Bu y\u00fck ve bile\u015fenleri SonoThera'ya \u00f6zeldir.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"which-tests-were-used-to-determine-if-full-length-dystrophin-production-was-achieved-did-you-measure-it-via-muscle-biopsy\"><strong>Tam uzunlukta distrofin \u00fcretiminin sa\u011flan\u0131p sa\u011flanmad\u0131\u011f\u0131n\u0131 belirlemek i\u00e7in hangi testler kullan\u0131ld\u0131? SonoThera bunu kas biyopsisi yoluyla m\u0131 \u00f6l\u00e7t\u00fc?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Evet. Tedavi sonras\u0131nda al\u0131nan kas biyopsileri kullan\u0131larak tam uzunlukta distrofin ekspresyonu de\u011ferlendirildi.<\/strong> Bu \u00f6rnekler, tam uzunluktaki distrofin proteininin varl\u0131\u011f\u0131n\u0131 do\u011frulamak i\u00e7in Western Blot dahil olmak \u00fczere kontroll\u00fc laboratuvar y\u00f6ntemleri kullan\u0131larak analiz edildi; ayr\u0131ca kas lifi biyoda\u011f\u0131l\u0131m\u0131n\u0131 ve zaman i\u00e7indeki uygun h\u00fccre alt\u0131 lokalizasyonunu de\u011ferlendirmek i\u00e7in imm\u00fcnohistokimya kullan\u0131ld\u0131.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"did-you-have-the-opportunity-to-see-the-creatine-kinase-ast-and-alt-results-how-much-did-these-values-decrease\"><strong>SonoThera'n\u0131n Kreatin Kinaz, AST ve ALT sonu\u00e7lar\u0131n\u0131 g\u00f6rme f\u0131rsat\u0131 oldu mu? Bu de\u011ferler ne kadar azald\u0131?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">AST, ALT ve ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n ek belirte\u00e7lerini de\u011ferlendirdik ve bug\u00fcne kadar hem k\u00fc\u00e7\u00fck hem de b\u00fcy\u00fck hayvan modellerinde tekli veya tekrarlanan tedavi sonras\u0131nda herhangi bir g\u00fcvenlik sorunu g\u00f6zlemlemedik.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eu anda, Duchenne hastal\u0131\u011f\u0131 modellerinin tam uzunlukta distrofin ile tedavi edilmesinin ard\u0131ndan kreatin kinaz (CK) d\u00fczeylerindeki azalmay\u0131 de\u011ferlendirme s\u00fcrecindeyiz.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"when-do-you-plan-to-begin-studies-on-humans\"><strong>SonoThera insan \u00fczerinde yap\u0131lacak \u00e7al\u0131\u015fmalara ne zaman ba\u015flamay\u0131 planl\u0131yor?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131na haz\u0131rlan\u0131yoruz ve d\u00fczenleyici kurumlar\u0131n onay\u0131n\u0131 beklemek ko\u015fuluyla, ilk insan klinik denememizi 2027 y\u0131l\u0131n\u0131n ilk yar\u0131s\u0131nda ba\u015flatmay\u0131 hedefliyoruz.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-road-to-clinic-trials\">Klinik ara\u015ft\u0131rmalara giden yol<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik ortam\u0131n d\u0131\u015f\u0131nda, geli\u015fen d\u00fczenleyici dinamikler SonoThera'n\u0131n konumunu daha da g\u00fc\u00e7lendirebilir. Hem FDA hem de EMA, \u00f6zellikle AAV tabanl\u0131 programlardaki aksakl\u0131klar\u0131n ve y\u00fcksek doz sistemik \u00e7al\u0131\u015fmalarda hasta \u00f6l\u00fcmlerine ili\u015fkin raporlar\u0131n ard\u0131ndan, da\u011f\u0131t\u0131m teknolojilerindeki ilerlemelere daha fazla \u00f6nem vermeye ba\u015flad\u0131. Tekrarlanan dozlamaya olanak tan\u0131yan g\u00fcvenli, vir\u00fcs i\u00e7ermeyen bir gen da\u011f\u0131t\u0131m yakla\u015f\u0131m\u0131n\u0131n g\u00f6sterilmesi, d\u00fczenleyici beklentileri \u015fekillendirmenin yan\u0131 s\u0131ra, alan genelinde gelecekteki akademik ara\u015ft\u0131rmalar\u0131 ve ticari platform stratejilerini de etkileyerek geni\u015f kapsaml\u0131 sonu\u00e7lar do\u011furabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SonoThera'n\u0131n teknolojik potansiyelinin bir k\u0131sm\u0131n\u0131 bile ger\u00e7ekle\u015ftirmesi durumunda, RIPPLE platformu yeni ortaya \u00e7\u0131kan bir inovasyondan, vir\u00fcs d\u0131\u015f\u0131 gen terapilerinin yeni nesli i\u00e7in temel bir \u00e7er\u00e7eveye d\u00f6n\u00fc\u015febilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><span style=\"text-decoration: underline;\">SonoThera'dan Hastalar ve Aileleri \u0130\u00e7in \u00d6nemli Duyuru:<\/span><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u00fctfen SonoThera'n\u0131n hi\u00e7bir ko\u015fulda ki\u015fisel t\u0131bbi bilgileri kabul edemeyece\u011fini veya inceleyemeyece\u011fini unutmay\u0131n. Zaman zaman, gelecekteki bir klinik deneye kat\u0131lma umuduyla t\u0131bbi ayr\u0131nt\u0131lar\u0131 payla\u015fmak isteyen hastalardan, ailelerden veya bak\u0131c\u0131lardan mesajlar al\u0131yoruz. Ancak, ge\u00e7erli yasalar ve d\u00fczenleyici gereklilikler, bu t\u00fcr bilgileri almam\u0131z\u0131, saklamam\u0131z\u0131 veya de\u011ferlendirmemizi kesinlikle yasaklamaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SonoThera ilk insan klinik denemesine ba\u015flad\u0131\u011f\u0131nda, duyuru resmi bir bas\u0131n b\u00fclteni ve \u015firketin sosyal medya kanallar\u0131 arac\u0131l\u0131\u011f\u0131yla kamuoyuna yap\u0131lacak ve onayl\u0131 bir klinik deneme veritaban\u0131ndaki \u00e7al\u0131\u015fma listesine do\u011frudan bir ba\u011flant\u0131 verilecektir. Okuyucular\u0131m\u0131z\u0131n yaln\u0131zca bu resmi ileti\u015fimlere g\u00fcvenmelerini ve g\u00fcncellemeleri web sitemiz, LinkedIn, BlueSky ve Twitter\/X hesaplar\u0131m\u0131z arac\u0131l\u0131\u011f\u0131yla takip etmelerini \u00f6nemle tavsiye ederiz. &gt;&gt;&gt; <a href=\"https:\/\/www.linkedin.com\/company\/sonothera\" target=\"_blank\" rel=\"noreferrer noopener\">LinkedIn<\/a> | <a href=\"https:\/\/bsky.app\/profile\/sonothera.bsky.social\" target=\"_blank\" rel=\"noreferrer noopener\">BlueSky<\/a> | <a href=\"https:\/\/x.com\/SonotheraI41798\" target=\"_blank\" rel=\"noreferrer noopener\">Twitter\/X<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>SonoThera, a biotechnology company dedicated to treat the root causes of human diseases by developing the next generation of genetic medicines, announced on January 8, 2026, that its proprietary RIPPLE\u2122 technology had detected strong and persistent full-length human dystrophin protein expression in the skeletal muscles of non-human primates, reaching up to 290% of normal levels. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5514,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[282],"tags":[66,359,432,285,286],"class_list":["post-5512","post","type-post","status-publish","format-standard","has-post-thumbnail","category-editorials","tag-duchenne-muscular-dystrophy","tag-full-length-dystrophin","tag-ripple","tag-sonothera","tag-ultrasound-mediated-delivery"],"subtitle":"Duchenne kas distrofisi (DMD) hastalar\u0131 ve aileleri, FDA onayl\u0131 gen terapisine ait \u00fc\u00e7 y\u0131ll\u0131k verileri tart\u0131\u015f\u0131rken, SonoThera ise RIPPLE ad\u0131n\u0131 verdi\u011fi vir\u00fcs i\u00e7ermeyen da\u011f\u0131t\u0131m platformunu geli\u015ftirmeye devam ediyor.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5512"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5512\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5514"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}